IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
The current price of IOBT is $0.04 USD — it has decreased by -28.45% in the past 24 hours. Watch IO Biotech stock price performance more closely on the chart.
What is IO Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IO Biotech stocks are traded under the ticker IOBT.
Is IO Biotech stock price growing?▼
IOBT stock has fallen by -78.22% compared to the previous week, the month change is a -87.97% fall, over the last year IO Biotech has showed a -95.78% decrease.
What is IO Biotech market cap?▼
Today IO Biotech has the market capitalization of 3.02M
When is the next IO Biotech earnings date?▼
IO Biotech is going to release the next earnings report on May 19, 2026.
What were IO Biotech earnings last quarter?▼
IOBT earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.21 USD resulting in a +20.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is IO Biotech revenue for the last year?▼
IO Biotech revenue for the last year amounts to 0 USD.
What is IO Biotech net income for the last year?▼
IOBT net income for the last year is -190.98M USD.
How many employees does IO Biotech have?▼
As of April 01, 2026, the company has 80 employees.